所有图片(2)
About This Item
经验公式（希尔记法）:
C20H21ClO4
CAS号:
分子量:
360.83
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
analytical standard
质量水平
方案
≥99.0% (HPLC)
保质期
limited shelf life, expiry date on the label
技术
HPLC: suitable
gas chromatography (GC): suitable
杂质
≤0.3% water
应用
forensics and toxicology
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2
InChI
1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
InChI key
YMTINGFKWWXKFG-UHFFFAOYSA-N
基因信息
human ... PPARA(5465)
正在寻找类似产品? 访问 产品对比指南
应用
有关合适的仪器技术的更多信息，请参阅产品的分析证书。想要获得更多支持，请联系技术服务部。
警示用语：
Warning
危险声明
预防措施声明
危险分类
STOT RE 2 Oral
靶器官
Liver
储存分类代码
11 - Combustible Solids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.
Rafael Simó et al.
Current medicinal chemistry, 20(26), 3258-3266 (2013-06-12)
Despite improving standards of care, people with diabetes remain at risk of development and progression of diabetic retinopathy (DR) and visual impairment. Identifying novel therapeutic approaches, preferably targeting more than one pathogenic pathway in DR, and at an earlier stage
Jonathan E Noonan et al.
Diabetes, 62(12), 3968-3975 (2013-11-23)
The drug fenofibrate has received major attention as a novel medical treatment for diabetic retinopathy (DR) and other diabetes-induced microvascular complications. This interest stems from two recent large, well-designed clinical trials that demonstrated large reductions in the progression of DR
Itoro E Elijah et al.
Burns : journal of the International Society for Burn Injuries, 38(4), 481-486 (2012-01-10)
Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric
Pitchai Balakumar et al.
Pharmacological research, 63(1), 8-12 (2010-11-26)
Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis. Dyslipidemia is a condition associated with elevated levels of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides, and reduced
Pascale Massin et al.
Ophthalmic epidemiology, 21(5), 307-317 (2014-08-19)
Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. In this double-blind, randomized, placebo-controlled study, 110 subjects with DME not
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门